Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation

Schwend, M.; Tiemann, Markus; Hh, Kreipe; Mr, Parwaresch; Eg, Kraatz; Herrmann, G.; Rp, Spielmann; Barth, Juergen

doi:10.1183/09031936.94.07030612

Cited by 14 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,19 The CD30 immunoreactivity of PTLD following conventional MST has been mentioned in previous reports and likely represents a state of activation in the EBV-infected B cells. 7,21,26 While monoclonality is not entirely specific for monomorphic PTLD, it is more suggestive. 17,21 Indeed, monoclonality can be demonstrated in most monomorphic PTLD by IgH PCR studies.…”

Section: Discussionmentioning

confidence: 96%

Posttransplant Lymphoproliferative Disorder Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Snyder

Stenzel²,

Buckley³

et al. 2004

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized complication of conventional bone marrow/stem cell and solid organ transplantation. However, not much is known about PTLD following the more recently introduced nonmyeloablative allogeneic stem cell transplantation (NMST). This study reports the findings from two cases of PTLD following NMST and compares them to the one previously reported case. The donor origin of the PTLD was determined using short tandem repeat analysis, and B- and T-cell clonalities were evaluated by polymerase chain reaction. Two cases of PTLD evolved in a total of 70 patients who have undergone NMST at our institution from 1999 to 2003. Both patients received conditioning with Fludarabine/Cytoxan/Campath 1H (alemtuzumab, anti-CD52 antibody) and T-cell-depleted donor cells with Campath-1H. Both PTLDs were EBV positive (by immunohistochemistry and in situ hybridization) with diffuse large B-cell lymphoma morphology. Our findings indicate the incidence of PTLD following NMST is 3% (2 of 70 patients from our institution and 1 of 30 from the previously reported case). All three PTLDs arose 6 to 7 months after NMST and were rapidly fatal. The pathology of the PTLD in all cases was donor origin, EBV positive, diffuse large B-cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 96%

Posttransplant Lymphoproliferative Disorder Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Snyder

Stenzel²,

Buckley³

et al. 2004

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…Diffuse large B‐cell lymphoma with or without CD30 expression defined the presentation in half of our cases and remains the most common form of EBV‐associated monomorphic PTLD. Large B‐cell lymphoma expressing CD30 has mainly been described in extranodal sites including the lung, gastrointestinal tract, and brain; their association with EBV infection has been previously made 21–23 . There are two prior reported cases of primary cutaneous CD30‐positive B‐cell lymphoma including one case associated with EBV infection 18 …”

Section: Discussionmentioning

confidence: 99%

Epstein–Barr virus‐associated B‐cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin

Verma

Frambach

Seilstad³

et al. 2005

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…The incidence of PTLD varies with the organ transplanted; rates of 1% for renal, 1.8 to 4.5% for cardiac, 2.1 to 2.2% for liver, 10% for lung, 11% for kidney-pancreas, 4.5 to 9.4% for heart-lung, and 14% for small bowel transplant recipients have been reported (215,238,475,557,743,765). The process is often multicentric and may involve the central nervous system, eyes, gastrointestinal tract (with bleeding and perforation), liver, spleen, lymph nodes, lungs, allograft, oropharynx, and other organs (2,103,178,183,190,258,334,407,472,475,496,556,559,616,644). Clinical presentations are varied and include a mononucleosislike syndrome with fever, adenopathy, tonsillitis and sore throat, fever (including "fever of unknown origin"), abdominal pain, anorexia, jaundice, bowel perforation, gastrointestinal bleeding, renal dysfunction, hepatic allograft dysfunction, pneumothorax, pulmonary infiltrates, and weight loss (76,250,475,696).…”

Section: Epstein-barr Virusmentioning

confidence: 99%

Infections in solid-organ transplant recipients

1997

View full text Add to dashboard Cite

Solid-organ transplantation is a therapeutic option for many human diseases. Infections are a major complication of solid-organ transplantation. All candidates should undergo a thorough infectious-disease screening prior to transplantation. There are three time frames, influenced by surgical factors, the level of immunosuppression, and environmental exposures, during which infections of specific types most frequently occur posttransplantation. Most infections during the first month are related to surgical complications. Opportunistic infections typically occur from the second to the sixth month. During the late posttransplant period (beyond 6 months), transplantation recipients suffer from the same infections seen in the general community. Opportunistic bacterial infections seen in transplant recipients include those caused by Legionella spp., Nocardia spp., Salmonella spp., and Listeria monocytogenes. Cytomegalovirus is the most common cause of viral infections. Herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and others are also significant pathogens. Fungal infections, caused by both yeasts and mycelial fungi, are associated with the highest mortality rates. Mycobacterial, pneumocystis, and parasitic diseases may also occur.

show abstract

Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation

Cited by 14 publications

References 20 publications

Posttransplant Lymphoproliferative Disorder Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Posttransplant Lymphoproliferative Disorder Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Epstein–Barr virus‐associated B‐cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin

Infections in solid-organ transplant recipients

Contact Info

Product

Resources

About